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                                                      1. ABSTRACT 
 
 
 
BACKGROUND: 
 
IHD is the leading cause of mortality and morbidity in the world. OSA has been 
established as one of the important modifiable risk factors for IHD. However, it is 
often undiagnosed and therefore, untreated. Though studies linking IHD and OSA 
have been published among western populations, there is a paucity of data from India 
about OSA and IHD. This study aims at identifying the relation between OSA and 
IHD among a cohort of patients diagnosed with IHD. 
 
 
METHODOLOGY: 
 
This study was a prospective observational study conducted among 70 patients 
undergoing evaluation for IHD at the Department of Cardiology, CMC Vellore. 
Data was collected using a standardized proforma. Subsequently, screening for OSA 
was performed using a portable screening device, the Apnea Link device.  
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RESULTS: 
 
The prevalence of OSA and OSAS among the study cohort was 75.7% and 18.6% 
respectively.  Nearly 50% of patients with OSA had mild OSA. The prevalence of 
metabolic syndrome and syndrome Z was 77.1% and 58.6% respectively.  
There was a statistically significant association between severity of OSA and severity 
of IHD based on coronary angiography and also presence of apneic episodes.  
Presence of snoring and apneic episodes were found to be important risk factors for 
development of OSA. 
 
 
CONCLUSION: 
 
This study is the first study from South Asia that attempts to study the relation 
between OSA and IHD in a cohort of patients with IHD. 
It establishes that OSA is more prevalent among IHD patients as compared to the 
general population, with a majority of patients having mild OSA. This also reveals the 
importance of screening for OSA among IHD patients, especially those with a history 
of snoring and apneic episodes. 
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                                                  2. INTRODUCTION 
 
Ischemic heart disease is one of the leading causes of death worldwide.  While it was 
earlier believed to be more prevalent in the developed nations, recent data has established 
IHD to be a vitally important public health issue even among developing nations.  A 
study has also demonstrated the increased prevalence of risk factors for IHD among south 
Asians and a resulting increased prevalence of IHD in this group as compared to other 
populations. Analysis of data from India also suggests that IHD is currently the leading 
cause of mortality in this country. 
       Advances in the knowledge about the etiology, risk factors and pathogenesis of IHD will  
       play a vital role in the management of IHD in the future. 
 
Obstructive Sleep Apnea is characterized by recurrent episodes of either partial or 
complete airway obstruction that results in fragmented sleep and intermittent hypoxemia. 
Community based studies done in North India have estimated the prevalence of OSA to 
be around 9%. Other studies have established the role of OSA as an important risk factor 
for IHD. However, it frequently remains undiagnosed and untreated in a majority of 
patients with one study estimating that 93% of women and 82% of men with moderate to 
severe obstructive sleep apnea remain undiagnosed and subsequently untreated. 
Thus, screening for OSA is of vital importance as timely detection and appropriate 
treatment of underlying OSA may play a role in both fastening the recovery process after 
an ischemic event and also in the prevention of subsequent recurrence of ischemic events. 
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Despite the high burden of morbidity and mortality due to IHD in India, there is a paucity 
of data regarding OSA and IHD. This study aims to identify the relationship between 
OSA and IHD in a tertiary care hospital in South India. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 3.AIM AND OBJECTIVES 
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              AIM: 
 
 
To examine the relationship between OSA and IHD in a cohort of patients diagnosed 
with IHD. 
 
OBJECTIVES: 
 
1. To assess the prevalence of OSA 
2. To assess the prevalence of OSAS 
3. To assess the severity of OSA 
4. To assess the prevalence of metabolic syndrome and syndrome Z  
5. To study the patterns of sleep disordered breathing  
6. To identify the risk factors for development of OSA 
7. To study the relationship between OSA and: 
a. Severity of IHD based on coronary angiography 
b. LV systolic function 
c. Body Mass Index 
d. Waist Circumference 
e. Neck Circumference 
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                                         4.REVIEW OF LITERATURE 
 
 
 
4.01 The Global Burden of IHD 
 
IHD is the leading cause of morbidity and mortality in the world. (1)(2)(3)(4)While 
the prevalence was initially estimated to be higher in high income countries, recent 
data suggests that it is a major public health concern even among middle and low 
income countries.(5) 
It has also been established that south Asians have a higher prevalence of risk factors 
for IHD, as compared to other parts of the world and this results in a higher 
prevalence among this population. (6) 
 
4.02 Mortality in IHD 
 
Data from the WHO from 2008, estimated that IHD is the single largest cause of 
death worldwide causing 7,249,000 deaths and accounting for 12.7% of total global 
mortality.(7) 
While IHD related mortality appears to be decreasing in high-income countries, it 
appears to be increasing in middle and low income countries and currently, middle 
and low income countries account for nearly 80% of all IHD related deaths.(7)(8) 
The Global burden of Disease study estimates that the annual global mortality due to 
IHD will be over 11 million by 2020.(9) 
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4.03 The Economic impact of IHD 
 
Data from the UK, published in 2002, estimates the total annual cost related to IHD to 
be over 7 billion pounds and it was the leading public health problem in terms of 
economic impact.(10) 
Data from the European Union published in 2003, estimates the annual economic 
impact of IHD on health care costs to be 169 billion euros, which is an average of 
3724 euros per capita per year. A total of 62% of this amount was related to direct 
costs and 21% to productivity loss.(11) 
Data from The US published in 2004, estimates the total annual cost related to IHD to 
be over 40 billion dollars.(12) 
 
4.04 The Indian Scenario 
 
The available data from India also suggests that it is the leading cause of morbidity 
and mortality. Data published in 2007 estimates that 32% of all deaths were related to 
IHD.(13)Other studies report that the prevalence of IHD is increasing.(14) The 
prevalence of IHD in India among general population aged between 35- 64 years is 
around 10%.(15) 
 
Mortality rates vary from region to region, ranging from 10% of all deaths in 
Meghalaya to 49% in Punjab. Punjab (49%), Goa(42%), Tamil Nadu (36%) and 
Andhra Pradesh (31%) have the highest IHD related mortality rates.(16) 
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The WHO has estimated that India lost 9 billion dollars in national income from 
premature deaths due to cardiovascular disease in 2005. (17) 
These losses are expected to cumulatively lead to 237 billion US dollars over the next 
10 years.(17) 
 
The Global burden of disease study suggests that there will be a rise in the number of 
Disability adjusted life years (DALY) due to IHD in the coming years in India—from 
a figure of less than 25 million DALYs in 1990, to over 30 million in 2020.(9) 
This is alarming, not just because of the increase in prevalence of IHD, but due to the 
fact that it will increasingly manifest in the economically active groups in society. 
 
 
4.05 Obstructive Sleep Apnea and Obstructive Sleep Apnea Syndrome 
 
Obstructive sleep apnea is the pathological occurrence of recurrent episodes of apnea 
and hypopnea during sleep owing to partial or complete pharyngeal obstruction, 
which leads to oxygen desaturation and sleep fragmentation.(18)(19) 
 
The occurrence of sleep apnea along with functional impairment like early morning 
fatigue and increased daytime somnolence is termed Obstructive sleep apnea 
syndrome.(20)(21) 
 
Apnea is defined as an episode of complete cessation of airflow lasting for atleast 10 
seconds. Hypopnea is defined as an episode of reduction of airflow (>50%) that 
results in a decrease of arterial oxygen saturation of atleast 4%.(22) 
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Apnea-hypopnea index is the ratio of the total number of apneic and hypopneic 
episodes and the total hours of sleep. Oxygen desaturation index is defined as the ratio 
of the total number of desaturation events (≥ 4% desaturation) and the total hours of 
sleep.(23) 
 
4.06 Metabolic syndrome and Syndrome Z 
 
         Metabolic syndrome is characterized by the presence of hypertension, 
dyslipidemia, increased blood glucose levels and abdominal obesity. 
 
The definition of metabolic syndrome as per the National cholesterol education 
program/ adult treatment panel (NCEP/ATP) III is the presence of any 3 of the 
following features:(24) 
 
• Abdominal obesity, defined as a waist circumference in men ≥102 cm (40 in) 
and in women ≥88 cm (35 in). 
• Serum triglycerides ≥150 mg/dLor drug treatment for elevated 
triglycerides. 
• Serum HDL cholesterol <40 mg/dL in men and <50 mg/dLin women or drug  
treatment for low HDL. 
• Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure. 
• Fasting plasma glucose (FPG) ≥100 mg/doll or drug treatment for elevated  
blood glucose.  
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Patients with obstructive sleep apnea are often overweight and obese and demonstrate 
features of metabolic syndrome. Syndrome Z is defined as the co-occurrence of OSA 
and metabolic syndrome.(25)(26)  
 
Obesity is emerging as a major public health problem worldwide, especially in 
developing countries like India. A study among adult Indians in urban areas has 
estimated 30-65% of population to be overweight, obese or have features of 
abdominal obesity. (27) There is also a difference in the prevalence of metabolic 
syndrome among urban areas and rural areas, with increased rates in urban areas.(28) 
 
Abdominal obesity has been identified as a risk factor for cardiovascular 
disease.(29)Studies have also suggested that it may be more important in the 
pathogenesis as compared to generalized obesity.(12)(30) Commonly used 
measurements of abdominal obesity include waist circumference and waist-hip ratio. 
It has also been shown that both these measurements can be used to predict risk of 
cardiovascular events.(31) 
Waist circumference can be measured easily and is less cumbersome as compared to 
waist-hip ratio. Further, changes in waist-hip ratio may not accurately reflect the 
extent of obesity or fluctuations in weight. Therefore, waist circumference is preferred 
over waist-hip ratio as measurement of abdominal obesity.(32) 
 
It has also been proposed that neck circumference may play a role in development of 
OSA(33) A study published in Turkey established the relationship of neck 
circumference and metabolic syndrome and OSA(34) 
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However, data suggests that the current definitions of overweight status and obesity 
among western population may not be applicable for Asian Indians and that Asian 
Indians may be at risk for development of obesity related complications at lower 
levels of Body mass index (BMI) and waist circumference (WC).(35) 
 
Subsequently, in 2009, the consensus statement for diagnosis of obesity, abdominal 
obesity and metabolic syndrome for Asian Indians was published.(32) 
 
According to this statement, obesity, abdominal obesity and metabolic syndrome were 
defines as follows: 
 
1. Obesity: 
 
       Normal BMI: 18.0-22.9 kg/m2 
       Overweight: 23.0-24.9 kg/m2  
       Obesity: >25 kg/m2 
 
2. Abdominal Obesity: (based on waist circumference) 
 
Men: 90 cm, women: 80 cm 
 
3. Metabolic syndrome: (presence of any 3 of the following): 
 
 Abdominal obesity, defined as a waist circumference in men ≥ 90cm 
and in women ≥80 cm. 
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 Serum triglycerides ≥150 mg/dL or drug treatment for elevated 
                           Triglycerides. 
 Serum HDL cholesterol <40 mg/dL in men and <50 mg/dL in women 
or drug treatment for low HDL. 
 Blood pressure ≥130/85 mmHg or drug treatment for elevated blood 
pressure. 
 Fasting plasma glucose (FPG) ≥100 mg/dL or drug treatment for 
elevated blood glucose.  
 
A study that compared OSA among normal weight, overweight and obese individuals 
revealed that OSA was less common among normal weight individuals as compared 
to the other groups and that in normal weight individuals, age and gender were 
predictive factors for OSA.(36) 
Data among south Asian population suggests that a majority of patients with OSA are 
not obese. Compared to the obese OSA patients, they have less prevalence of 
hypertension and severity of OSA is mild.(37) 
 
While it is well known that obesity is a risk factor for OSA, a recent study has 
established a positive association between severity of OSA and likelihood of 
increased BMI over a duration of 5 years.(38) 
 
The relationship between OSA and metabolic disorders is multi-directional and 
complex.(39)(40) 
Obesity is considered to be one of the main causes for OSA.It is also likely that 
metabolic syndrome may play a role in development of OSA. Conversely, OSA may 
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be a risk factor for metabolic disorders like hypertensionand insulin 
resistance.(41)(42)(43)(44)Both Human and animal studies have revealed the 
relationship between OSA and dyslipidemia, independent of obesity.(45)(46)(47) 
 
Studies in a western population had shown that the prevalence of metabolic syndrome 
is higher in patients with OSA(48)(49) 
Subsequently, data from India has revealed that OSA is independently associated with 
metabolic syndrome in Asian Indians.(50)(51) 
It has also been proposed that OSA may be one of the manifestations of metabolic 
syndrome.(52)(53) 
It has also been shown that metabolic syndrome is significantly associated with 
cardiovascular disease and can also predict cardiac morbidity and mortality in healthy 
subjects with a family history of ischemic heart disease.(54) 
 
4.07 Mechanisms of cardiovascular pathogenesis in Obstructive sleep apnea 
 
 
OSA has been thought to cause cardiovascular disease through a combination of 
various factors:(55)(56)(57)(58)(59)(60)(61)(62)(63)(64) 
 
 Intermittent hypoxia 
 Inflammation 
 Oxidative stress that can cause atherosclerosis 
 Endothelial dysfunction 
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Intermittent hypoxia is recognized as the pivotal feature of OSA. This leads to 
activation of selective inflammatory pathways that cause increased expression of 
inflammatory cytokines, chemokines and adhesion molecules. This leads to vascular 
endothelial dysfunction.(65)(66) It has also been shown that OSA is associated with 
endothelial dysfunction, independent of obesity.(67) It has also been shown that the 
degree of endothelial dysfunction is dependent on the severity of intermittent 
hypoxia.(68) Studies among patients with OSA and IHD have estimated the lowest 
nocturnal saturation values to be between 86.1-86.7%. (21)(69) 
 
It has also been shown that episodes of hypopnea with desaturation of atleast 4% are 
associated with increased cardiovascular risk and that there is no risk with hypoxic 
epsiodes of lesser severity.(70) The mechanisms postulated to explain the 
cardiovascular pathogenesis include myocardial ischemia and cardiac 
arrhythmias.(71) 
 
Animal models have also proven the role of intermittent hypoxia in increasing 
susceptibility to myocardial infarction.(72) 
This has been shown to occur due to increased oxidative stress.(73) 
The oxidative stress has been shown to be due to activation of NADPH oxidase and 
other free oxygen radicals.(74) 
 
The other molecular biomarkers of endothelial dysfunction include:(75)(76)(77)(78) 
 
 Endothelial nitric oxide synthase (eNOS) 
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 Tumour necrosis factor- alpha induced protein 3 (TNF- AIP 3) 
 Hypoxia inducible factor 1 alpha (HIF 1 alpha) 
 Vascular endothelial growth factor (VEGF) 
 C-reactive protein (CRP) 
 Brain natriuretic peptide (BNP) 
 Heart type fatty acid binding protein (h FABP) 
 Neopterin 
 
 
Serum Adiponectin is another protein bio-marker for OSAS and it is shown to 
significantly decreased among patients with moderate and severe OSAS.(79) 
 
It has been proven that the frequency of non-calcified coronary plaques are higher 
among patients with OSA than among non-OSA patients.(80) Patients with OSA also 
have more number of vessels involved and greater severity of stenosis.(81) 
 
Even among patients with no history of IHD, the presence of OSA is associated with 
increased risk of subclinical atherosclerosis.(82) 
Autonomic dysfunction has also been documented in patients with OSA.(83)(84)(85) 
Abnormally elevated sympathetic activity is implicated in the development of 
secondary hypertension.(86) 
 
It has been shown that in patients with heart failure and OSA, the degree of daytime 
somnolence is less as compared to patients with OSA alone. Also, in this group the 
degree of daytime somnolence does not correlate with the AHI. This is postulated to 
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be due to increased sympathetic activity in patients with heart failure and OSA.(87) 
 
It has also been shown that the prevalence of OSA increases with age in both sexes 
and the relative risk has been calculated as 2.2 with each 10 year increase in age.(88) 
 
 
4.08 Obstructive Sleep Apnea and Ischemic Heart Disease 
 
The Earliest population based studies had documented the relationship between 
snoring and hypertension and between snoring and IHD.  
Subsequently, numerous recent studies have suggested the role of OSA as an 
important modifiable risk factor for 
IHD.(89)(90)(91)(92)(93)(94)(95)(96)(97)(98)(99)(100) 
 
 
Studies done among patients with IHD, estimate the prevalence of OSA to be between 
50-65%.(101)(102)(21)(103) 
Data also suggests that a majority of patients with OSA and IHD have mild 
OSA.(21)(103)  
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                           Studies showing association between OSA and IHD 
 
 
Author Name (Reference 
number in bibliography) 
 
 
              Study group characteristics 
 
 OSA prevalence 
De Olazabal (100) N= 17 male patients with IHD proven by  
angiography 
 
65% 
Andreas (101) N= 47 male patients, 3 female patients with IHD  
proven by angiography 
 
50% 
Mooe (21) N= 142 male patients with IHD proven by  
angiography 
 
61% 
Mooe (102) N= 102 female patients with IHD proven by 
angiography 
 
54% 
 
 
Studies have also estimated the relative risk for IHD in people with OSA as compared 
to controls to be between 4.1-4.5.(21)(103) 
A meta-analysis estimated the relative risk for IHD in patients with moderate and 
severe OSA to be 1.40 and 2.65 respectively.(104) 
 
A follow-up study published in 2011 done among patients with acute ST elevation 
myocardial infarction, showed that the risk of recurrence of ischemic events was 
higher among patients with OSA and the survival rate was correspondingly 
lower.(105) 
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It has also been shown that the severity of OSA is an important predictor of mortality 
due to cardiovascular events.(106)(107) 
 
The severity of OSA has been found to be associated with increased risk of IHD as 
shown in the Sleep heart health study.(108) 
 
Single photon emission CT studies have shown impaired ventricular function and 
decreased coronary reserve among OSA patients as compared to controls.(109) 
OSA has also been determined to be an important factor in the development and 
progression of heart failure.(110)(111) 
 
Conversely, cardiac status has also been found to affect the severity of OSA as 
established by a recent study conducted in patients with acute myocardial infarction 
and OSA, wherein an improvement in left ventricular function after the acute event 
was found to correlate with an alleviation in the sleep apnea.(112) 
Even among patients with cardiac failure, treatment of underlying OSA has been 
shown to associated with better mortality outcomes.(113) 
 
OSA is also associated with increased risk of sudden cardiac death. Nocturnal 
Hypoxemia, which is an important feature of OSA, has been determined to be an 
important risk factor for sudden cardiac death.(114) 
 
Thus, it has been suggested, based on available data that all patients with IHD should 
be screened for OSA and that all patients with OSA should be screened for 
IHD.(115)(116) 
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4.09 Screening for Obstructive sleep apnea 
 
OSA is frequently undiagnosed and one study estimated that 93% of women and 82% 
of men with moderate and severe OSA remain undiagnosed.(117) 
A lack of awareness among treating physicians is cited as the primary reason for the 
deficit in diagnosis and treatment.(118) 
Although full polysomnography is the diagnostic test of choice, a screening device 
that provides reliable information and is simple and easy-to-use would be useful.(119) 
 
The Apnealink device is a single channel screening tool for sleep apnea that measures 
airflow through a nasal cannula connected to a pressure transducer, thereby providing 
AHI. Studies comparing the device to Polysomnography, have demonstrated the high 
sensitivity and specificity of the device.(120)(121)(122)(123)(124) 
 
 
STOPBANG questionnaire: 
 
The STOPBANG questionnaire is a simple and easy to use screening tool for OSA. 
It was initially developed as a screening tool for use among surgical patients. Initial 
studies had revealed high sensitivity for OSA.(125) 
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Other studies have revealed that a STOPBANG score of 5-8 identified patients with 
high probability of moderate and severe OSA.(126)(127) 
Subsequently, The STOPBANG questionnaire was adapted for an Asian population 
with the BMI cut-off changed to 30 kg/mt
2
.  (128) 
 
 
Pictorial Epworth Sleepiness Scale: 
 
The Epworth sleepiness scale was developed in 1991 and has become one of the most 
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commonly used questionnaires for increased daytime somnolence.(129) 
As it is designed to be self-administered, many patients often have difficulty 
understanding and completing the ESS. 
Subsequently, a pictorial version of the ESS was developed and published in 2011. 
(130) 
It was found to be comparable to the standard ESS and a majority of patients found it 
to be very easy and preferred it over the standard ESS. 
A score ≥ 11 is considered to be abnormal. 
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4.10 Grading of severity of Obstructive sleep apnea 
 
 
The severity of OSA is graded as follows:(119) 
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 Severity of OSA AHI 
1.Mild 5-15 
2.Moderate 16-30 
3.Severe >30 
 
 
 
 
4.11Treatment for Obstructive sleep apnea 
 
CPAP was first described as a possible treatment for OSA in 1981 by Sullivan.(131) 
Subsequently, it has been established that CPAP is the standard treatment for 
OSA.(132)(133)(134)(135) 
Studies have also established that treatment with CPAP reduces risk of future 
ischemic cardiac events.(136)(137)(138) 
 
The mechanisms postulated to explain the action of CPAP in OSAS are:(139)(140) 
1. reduced upper airway resistance due to prevention of sleep induced 
collapse of the airway 
2. stimulation of mechanoreceptors leading to increased airway tone. 
3. Role in opposing inflammation, oxidative stress and endothelial 
dysfunction 
 
Other studies have shown that the application of CPAP would eliminate snoring as 
well as obstructive sleep apnea.(141) 
Subsequent studies have also shown that long term adherence to CPAP is around 
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70%, which is comparable to therapies for other chronic 
disorders.(142)(143)(144)(145) 
 
 
 
 
4.12The Global Scenario 
 
Studies done in general adult populations in the west have estimated the prevalence of 
OSA to be between 3-7% and OSAS to be between 1-4%.(146)(20)(147) 
 
4.13The Indian Scenario 
 
A population-based study done in New Delhi, estimated the prevalence of OSA and 
OSAS to be 9.3% and 2.8% respectively.(148) Another population based study, also 
from New Delhi, estimated the prevalence of OSA and OSAS to be 13.74% and 
3.57%.(149) 
 
A study, done in Orissa, among an urban population, estimated the prevalence of 
metabolic syndrome to be 33.5%.(150) Another population based study from Jaipur 
showed the prevalence of metabolic syndrome to be 31.6%.(151) Another population 
based study from Mumbai has estimated the prevalence of metabolic syndrome to be 
19.52%.(152) A hospital based study done among patients with OSA has estimated 
the prevalence of metabolic syndrome to be 74%.(153) 
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A study from New Delhi among general population has estimated the prevalence of 
syndrome Z to be 4.5%.(154) However, hospital based studies among patients with 
OSA has estimated the prevalence of syndrome Z to be between 65-79%.(155)(153) 
 
 
 
4.14 Relevance of this study 
 
OSA has been shown to be a significant independent modifiable risk factor for IHD. 
There is a paucity of data from India about prevalence of OSA among the general 
population and among those diagnosed with IHD, as compared to western 
populations. Thus, any advances in the scientific knowledge about the pathogenesis of 
OSA and its relationship with IHD will have a vital role in management of IHD in the 
future. 
 
 
This is particularly significant, when we consider that: 
 
1. IHD is the most common cause of mortality and morbidity in India 
2. Reports suggest that the prevalence of IHD is on the rise 
3. In the future, IHD will increasingly occur among the economically active 
groups in society, which would result in enormous losses to the economy, 
both in terms of direct and indirect medical expenditure 
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This study attempts to study the following in a cohort of IHD patients: 
 
1. Prevalence of OSA, OSAS, metabolic syndrome and syndrome Z 
2. Severity of OSA 
3. Patterns of sleep disordered breathing 
4. Relationship between OSA and: 
 Severity of IHD, based on angiography 
 LV systolic function 
 BMI 
 Waist circumference 
 Neck circumference 
 
This is the first study from South Asia that attempts to look at these aspects. 
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                                     5. MATERIALS AND METHODS 
 
5.1 STUDY DESIGN 
 
This is a prospective observational study done among patients who are undergoing 
evaluation of Ischemic Heart Disease at The Department of Cardiology, CMC 
Vellore. 
 
Study Setting: 
 
CMC, Vellore is a 2200 bedded, tertiary care, multi-specialty teaching hospital 
located in Tamil Nadu, which caters to the demands of not only people from Tamil 
Nadu, but from all over India. 
 
 
5.2 IRB APPROVAL 
 
This study was reviewed and cleared by the Institutional Review Board (IRB Min. 
7751 dated 06/02/2012) and The Ethics Committee, CMC, Vellore. 
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5.3 INCLUSION CRITERIA 
 
 
1. Patients willing to give informed signed consent 
2. Patients of both sexes, aged between 30-85 years 
3. Diagnosis of Ischemic heart disease- 
 Patients with a history of documented myocardial infarction 
(STEMI/NSTEMI) (> 90 days before date of informed consent) 
 Patients who had undergone PTCA previously (with/ without stent)(>90 days 
before date of informed consent) 
 Patients who had undergone CABG previously (> 1 year before date of 
informed consent) 
 Patients in whom diagnosis of IHD was made by coronary angiography  
 
 
 
5.4 EXCLUSION CRITERIA 
 
 
1. Patients who have already been initiated on long term domiciliary oxygen 
therapy 
2. Patients who have been diagnosed with severe and very severe COPD  
             (Fev1/FVC< 70% and Post bronchodilator Fev1<50%) 
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5.5 STUDY DURATION 
 
The duration of the study was 16 months. (01/04/2013- 31/07/2013) 
 
5.6 DATA COLLECTION 
 
A standardized profoma was used for collection of relevant data during 
assessment and this included demographic data, medical history, clinical 
assessment and investigations. The data was subsequently entered onto a 
standardized Microsoft Excel spread sheet. 
 
5.7 STUDY METHODOLOGY 
 
All adult patients, who were admitted for evaluation of IHD at the department of 
Cardiology were screened. Among these patients, those who satisfied the inclusion 
criteria, those willing to give informed signed consent for the study and those willing 
to undergo a sleep study with a portable screening device were included. 
 
The patients and the relatives were initially explained about: 
 
1. Clinical manifestations of Obstructive sleep apnea 
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2. The aim of this study wherein it was planned to study the relationship between 
OSA and IHD.  
3. The methodology of this study wherein screening for OSA was planned using 
a portable screening device at the bedside 
 
They were then given the patient information sheet, in a language that they could 
comprehend. Subsequently, if the patients were willing to participate in the study, 
signed consent was obtained on the consent form. 
Subsequently, a brief history was obtained that included details of co-morbidities and 
details of sleep pattern and sleep disordered breathing. A brief physical examination 
was also performed that included general examination and assessment of vital signs. 
Relevant data was noted from the laboratory investigations performed as well as  
findings from the 2D Echocardiogram. All the data was entered into the proforma. 
 
The proforma also had a pictorial version of the ESS and the patients were requested 
to enter the appropriate information. 
Subsequently, the portable screening device was connected in the night once the 
patient was ready to go sleep and it was disconnected the next morning. The data was 
subsequently retrieved from the device for analysis. 
 
 
5.8 ANALYSIS 
 
Microsoft Excel was used for data entry and Statistical Package for Social Sciences 
(SPSS) Version 16 was used for analysis.  
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The data was divided into continuous and nominal varieties and was analysed 
appropriately.  The data was expressed as mean (standard deviation) for continuous 
variables and rates for nominal variables. The pearsons’s correlation coefficient was 
calculated for continuous variables. The differences between means were analysed 
using independent t test or one way ANOVA as appropriate. 
Differences were considered significant for p values less than 0.05. 
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                                                      6. RESULTS 
 
          
 
 
             Table I. CLINICAL CHARACTERISTICS OF PATIENTS- A 
 
 
 
  
              
                   Cases (N= 70) 
1. Age (years)* 56.76 (8.76) 
2. Male gender** 55 (78.6%) 
3. Diabetes Mellitus** 37 (52.9%) 
4. Hypertension** 46 (65.7%) 
5. Dyslipidemia** 18 (25.7%) 
6. Hypothyroidism** 3 (4.3%) 
7. BMI (Kg/Mt
2 
)* 28.04 (3) 
8. Neck Circumference (cms)* 38.85 (2.12) 
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9. Waist circumference (men)(cms)* 88.47 (9.32) 
    Waist circumference (women)(cms)* 84.80 (10.75) 
10. Weight (Kg)* 73.57 (8.63) 
11. Metabolic Syndrome** 54 (77.1%) 
 
 
* Mean (Standard deviation) 
 
** Number (Percentage) 
 
 
 
Criteria for definition of Metabolic syndrome: (presence of any 3 of the 
following): (32) 
 
 Abdominal obesity, defined as a waist circumference in men ≥ 90cm 
and in women ≥80 cm. 
 Serum triglycerides ≥150 mg/dL or drug treatment for elevated 
                        Triglycerides. 
 Serum HDL cholesterol <40 mg/dL in men and <50 mg/dL in women 
or drug treatment for low HDL. 
 Blood pressure ≥130/85 mmHg or drug treatment for elevated blood 
pressure. 
 Fasting plasma glucose (FPG) ≥100 mg/dL or drug treatment for 
elevated blood glucose.  
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            Table II. CLINICAL CHARACTERISTICS OF PATIENTS- B 
 
 
 
 Cases (N=70) 
1. History of Myocardial Infarction* 17 (24.3%) 
2.Type of Myocardial Infarction  
    a. ST elevation MI 14 (82.4%) 
    b. Non ST elevation MI   3 (17.6%) 
3. Results of Coronary Angiography*  
    a. Single vessel disease 22 (31.4%) 
    b. Double vessel disease  20 (28.6%) 
    c. Triple vessel disease 16 (22.9%) 
    d. Minor Coronary artery disease 12 (17.9%) 
4. Number of patients who underwent  
    Coronary Angioplasty * 
34 (48.6%) 
5. Number of patients who underwent    
    Coronary Angioplasty followed by    
    Coronary artery Stenting * 
 
33 (47.1%) 
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6. Number of patients who underwent  
    Coronary Artery Bypass Grafting  
    Surgery* 
  4 (5.7%) 
 
* Number (Percentage) 
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                        Table III. 2D ECHOCARDIOGRAM RESULTS 
 
 
 
 
 
 
LV systolic function (Ejection fraction) Cases (N=70) 
1. Normal (EF> 55%)* 48 (68.6%) 
2. LV systolic dysfunction* 22 (31.4%) 
     a. mild (EF: 45-54%)   4  (18.2%) 
     b. moderate (EF: 36-44%) 16  (72.7%) 
     c. severe (EF: ≤ 35%)   2   (9.1%) 
 
 
* Number (Percentage) 
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   ** The grading of LV systolic function in terms of LV ejection fraction:(157) 
 
1. Normal: LV EF ≥ 55% 
2. Mild LV dysfunction: LV EF: 45-54% 
3. Moderate LV dysfunction: LV EF 36-44% 
4. Severe LV dysfunction: LV EF ≤ 35% 
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              Table IV. PATTERNS OF SLEEP DISORDERED BREATHING 
 
 
 
 
Sleep Pattern Cases (N=70) 
1.Presence of snoring** 54 (77.1%) 
2.Does snoring affect other people** 45 (83.3%) 
3.Loudness of snoring** (156)  
   a. loud as breathing 1    (1.9%) 
   b. loud as talking 3    (5.6%) 
   c. louder than talking 23  (42.6%) 
   d. very loud 27  (50%) 
4.Frequency of snoring**  
   a. almost everyday 41   (75.9%) 
   b. 3-4 times per week 12   (22.2%) 
   c. 1-2 times per week 1     (1.9%) 
5.Occurence of breathing pauses 25   (46.2%) 
6.Frequency of breathing pauses  
    a. almost everyday 25 
7.Presence of Morning fatigue** 53  (75.7%) 
8.Presence of Morning fatigue and  
   increased Daytime somnolence** 
 
13 (18.6%) 
9. STOPBANG criteria positive (≥3)** 
 
65 (92.8%) 
10. Pictorial Epworth Sleepiness scale      7.90 (3.16) 
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      score among all 70 patients* 
11. Pictorial Epworth Sleepiness scale      
      score among 53 patients with OSA* 
9.01 (2.69) 
12. Pictorial Epworth Sleepiness scale      
      score among 13 patients with OSAS* 
12.61 (1.50) 
 
 
 
 
 
 
 
 
* Mean (Standard deviation) 
 
**Number (Percentage) 
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                                  Table V. SLEEP STUDY RESULTS 
 
 
 
 CASES (N=70) 
1.Presence of Obstructive Sleep Apnea    
   (AHI≥5)** 
53 (75.7%) 
2. Presence of Obstructive Sleep Apnea  
   Syndrome** 
13 (18.6%) 
3.Presence of Syndrome Z** 41 (58.6%) 
 
 
 
4. Mean Apnea Hypopnea Index among     
    the entire group of 70 patients 
18.27 (17.54) 
5. Mean Oxygen Desaturation Index   
   among the entire group of 70 patients 
 
21.04 (18.51) 
 
 
 
6. Mean Apnea Hypopnea Index among     
    the 53 patients diagnosed with OSA* 
23.75 (16.79) 
7. Mean Oxygen Desaturation Index   
   among the 53 patients diagnosed with  
   OSA* 
27.06 (17.39) 
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8. Mean Lowest Oxygen saturation 
   among the 53 patients diagnosed with  
   OSA* 
73.71 (13.48) 
 
9. Mean Apnea Hypopnea Index among     
    the 13 patients diagnosed with OSAS* 
32.53 (19.64) 
10. Mean Oxygen Desaturation Index   
     among the 13 patients diagnosed with  
     OSAS* 
35.15 (20.87) 
11. Mean Lowest Oxygen saturation 
      among the 13 patients diagnosed with  
      OSAS* 
72.61 (13.42) 
 
 
 
 
* Mean (Standard deviation) 
 
**Number (Percentage) 
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                   Table VI. SEVERITY OF OBSTRUCTIVE SLEEP APNEA 
 
 
 
 N= 53 
Apnea hypopnea index*  
5-15 26(49.1%) 
16-30 13(24.5%) 
>30 14(26.4%) 
Oxygen desaturation index*  
5-15 22(41.5%) 
16-30 11(20.8%) 
>30 20(37.7%) 
 
* Number (Percentage) 
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Table VII. OSA AND LOUDNESS OF SNORING (52 PATIENTS)** 
 
 
 
 
 
 
Loudness of 
snoring 
Number of patients AHI* ODI* 
Loud as breathing              1 11 24 
Loud as talking              3 26.67 (32.39) 21.22 (21.22) 
Louder than talking             21 22.47 (15.57) 27.09 (16.01) 
Very Loud             27 25.59 (16.47) 27.59 (19.03) 
 
 
 
 
* Mean (standard deviation) 
 
 
** 53 patients were diagnosed to have OSA. In this group, 1 patient did not snore. 
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              Table VIII. OSA AND APNEIC EPISODES (52 PATIENTS)** 
 
 
 
 
 
 
 Patients having history of apneic 
episodes 
Patients without 
history of apneic 
episodes 
p value 
Number of patients 25 27 ----- 
AHI* 30.40 (17.44) 18.29 (14.01) 0.008 
ODI* 33.44 (19.07) 21.74 (13.81) 0.014 
 
 
 
 
* Mean (standard deviation) 
 
 
** 53 patients were diagnosed to have OSA. In this group, 1 patient did not snore. 
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               Table IX. OSA AND SEVERITY OF IHD (53 patients) 
 
 
 
 
 
 Minor CAD Single vessel 
disease 
Double vessel 
disease 
Triple vessel 
disease 
Number 9 16 17 11 
AHI* 18.56(13.51) 17.44(12.31) 25.41(17.63) 34.64(19.3) 
ODI* 21.78(14.34) 20.50(13.95) 27.71(19.28) 39.91(15.64) 
 
 
 
 Single vessel 
disease 
Double vessel 
disease 
Triple vessel 
disease 
p value 
Number 16 17 11 ----- 
AHI* 17.44(12.31) 25.41(17.63) 34.64(19.3) 0.036 
ODI* 20.50(13.95) 27.71(19.28) 39.91(15.64) 0.018 
 
 
 
 
     * Mean (Standard deviation) 
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       Table X. OSA AND LV SYSTOLIC FUNCTION **(53 patients) 
 
 
 
 Normal 
 
 
LV EF≥ 55% 
Mild LV 
dysfunction 
 
LV EF:  
45-54% 
Moderate LV 
dysfunction 
 
LV EF:  
36-44% 
Severe LV 
dysfunction 
 
LV EF≤ 35% 
Number 36 2 13 2 
AHI* 21.36(16.18) 17(4.24) 30.31(18.56) 31(19.79) 
ODI* 24.58(16.28) 24(21.21) 34(18.88) 29.50(28.99) 
 
 
 Mild LV 
dysfunction 
Moderate LV 
dysfunction 
Severe LV 
dysfunction 
p value 
Number 2 13 2 ----- 
AHI* 17(4.24) 30.31(18.56) 31(19.79) 0.623 
ODI* 24(21.21) 34(18.88) 29.50(28.99) 0.790 
 
     * Mean (Standard deviation) 
 
 
 
                            PEARSON’S CORRELATION COEFFICIENT 
 
 
AHI and LV EF -0.218 
ODI and LV EF -0.215 
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     ** The grading of LV systolic function in terms of LV ejection fraction:(157) 
 
Normal: LV EF ≥ 55% 
Mild LV dysfunction: LV EF: 45-54% 
Moderate LV dysfunction: LV EF 36-44% 
Severe LV dysfunction: LV EF ≤ 35% 
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                               Table XI. OSA AND BMI (53 patients) 
 
 
 
 
 
 
 Overweight Obese p value 
Number 6 47 ----- 
AHI* 16.67(7.60) 24.66(17.47) 0.277 
ODI* 19.17(9.06) 28.06(17.99) 0.242 
 
     * Mean (Standard deviation) 
 
                            PEARSON’S CORRELATION COEFFICIENT 
 
 
AHI and BMI 0.08 
ODI and BMI 0.169 
 
 
 
                            PEARSON’S CORRELATION COEFFICIENT 
 
 
AHI and weight 0.013 
ODI and weight 0.105 
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              Table XII. OSA AND WAIST CIRCUMFERENCE (53 patients) 
 
 
 
 
 
 
Men: (42 patients) 
 
 
 
 < 90 cms > 90 cms p value 
Number 23 19 ----- 
AHI* 27.17(15.47) 22.68(20.04) 0.417 
ODI* 28.22(16.94) 25.79(19.01) 0.664 
 
 
 
Women: (11 patients) 
 
 
 
 < 80 cms > 80 cms p value 
Number 6 5 ----- 
AHI* 14.50(6.71) 23.70(16.90) 0.274 
ODI* 25.50(16.19) 28.40(19.45) 0.793 
 
 
     * Mean (Standard deviation) 
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              Table XIII. OSA AND NECK CIRCUMFERENCE (53 patients) 
 
 
 
 
 
 < 40 cms >40 cms p value 
Number 36 17 ----- 
AHI* 21.42(15.24) 28.71(19.24) 0.142 
ODI* 26.86(17.03) 27.47(18.62) 0.907 
 
 
 
 
     * Mean (Standard deviation) 
 
 
 
 
 
 
 
 
                            PEARSON’S CORRELATION COEFFICIENT 
 
 
AHI and NC 0.255 
ODI and NC 0.124 
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      Table XIV. THE SIGNIFICANCE OF NOCTURNAL DESATURATION IN          
                                         PATIENTS DIAGNOSED WITH OSA 
 
 
     Lowest nocturnal oxygen saturation and LV systolic dysfunction (17 patients) 
 
 
 Mild LV 
dysfunction  
Moderate LV 
dysfunction 
Severe LV 
dysfunction 
p value 
Number of 
patients 
2 13 2 ----- 
Lowest 
nocturnal 
oxygen 
saturation 
68 (25.45) 69.38 (17.09) 75 (18.38) 0.908 
 
 
 
 
     * Mean (Standard deviation) 
 
 
 
                            PEARSON’S CORRELATION COEFFICIENT 
 
 
LV ejection fraction vs. Lowest nocturnal 
oxygen saturation 
0.133 
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           Lowest nocturnal oxygen saturation and severity of IHD (44 patients) 
 
 
 Single vessel 
disease  
Double vessel 
disease 
Triple vessel 
disease 
p value 
Number of 
patients 
16 17 11 ----- 
Lowest 
nocturnal 
oxygen 
saturation 
75.18 (14.44) 77.11 (12.40) 65.90 (14.13) 0.1 
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 Table XV. The Risk factors for OSA among IHD patients (70 patients) 
 
 
 
 Number (70) OSA (53) No OSA (17) p value 
Diabetes 37 27 10 0.592 
Hypertension 46 34 12 0.772 
Dyslipidemia 18 11 7 0.116 
Hypothyroidism 3 3 --- 1.000 
Metabolic 
syndrome 
54 41 13 0.589 
BMI (mean) --- 28.32 27.15 0.162 
Neck 
Circumference 
(mean) 
--- 39.35 37.29 <0.001 
Presence of 
snoring 
54 52 2 <0.001 
Occurrence of 
apneic episodes 
25 25 --- <0.001 
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              Table XVI. Odds Ratio of snoring and OSA among IHD patients 
 
 
Out of 70 patients, there were 53 patients diagnosed with OSA. 
Out of 70 patients, there were 54 patients who had a history of snoring. 
 
Out of the 54 patients with a history of snoring, 52 patients had OSA. 
Out of the 16 patients who did not have a history of snoring, 1 patient had OSA. 
 
 
 
                                            
 OSA positive OSA negative 
Snoring present 52 2 
Snoring absent 1 15 
      
 
 
 
Therefore in the study cohort, the odds ratio that a patient with snoring would 
have OSA is 390. 
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A total of 70 patients with a diagnosis of IHD were included in the study. 
 
Clinical characteristics of patients (Table I, II) 
 
Among the patients included, nearly 80% of the patients were men and the mean age 
was 56.7 years. While Diabetes and hypertension were present in over 50% of 
patients, over 25% of patients had dyslipidemia. 
The mean BMI was 28 and nearly 80% of patients had features of metabolic 
syndrome. 
 
17 patients had a history of myocardial infarction with over 80% of these patients  
having had a ST elevation MI. 
Over 30% of patients had single vessel disease on angiography. 20 patients had 
double vessel disease with 16 patients having triple vessel disease. 
 
Nearly 50% of patients underwent coronary angioplasty. All these patients, with the 
exception of 1 patient, underwent coronary artery stenting. 4 patients underwent 
CABG. 
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     Figure I. Presence of comorbidities among the cohort of 70 patients 
 
 
 
 
 
 
 
 
 
                   Figure II. Results of Coronary Angiography (70 patients) 
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2D Echocardiogram results (Table III) 
 
Of the 70 patients, nearly 70% had normal LV systolic function. Among the 22 
patients who had LV systolic dysfunction, over 70% had moderate LV dysfunction. 
 
 
 
 
 
 
 
Figure III. LV Systolic function based on 2D Echocardiogram (70 patients) 
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Patterns of sleep disordered breathing (Table IV) 
 
Of the 70 patients, 54 patients gave a history of snoring with 50% of these patients 
having very loud snoring. Over 75% of these patients also gave a history of daily 
snoring. 
Of the 54 patients who had a history of snoring, 25 patients gave a history of apneic 
episodes occurring daily. 
Over 75% of patients gave a history of morning fatigue while only 18.6% gave a 
history of increased daytime somnolence along with morning fatigue. 
The STOPBANG criteria were positive in over 90% of patients. 
 
The mean Epworth score in the entire group was 7.90. However, it was 9.01 and 
12.61 among the 13 patients diagnosed with OSA and OSAS respectively. 
 
 
 
                           Figure IV. Loudness of snoring (54 patients) 
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Sleep study results (Table V) 
 
 
Of the 70 patients, over 75% of patients had OSA while the prevalence of OSAS was 
18.6%. Nearly 60% of patients had features of syndrome Z. 
 
The mean AHI and ODI in the entire group of 70 patients was 18.27 and 21.04 
respectively. Among the 53 patients who were diagnosed to have OSA, the mean AHI 
was 23.75 and the mean ODI was 27.06. The mean lowest oxygen saturation among 
the 53 patients diagnosed with OSA was 73.71%. The mean AHI and ODI among the 
13 patients diagnosed with OSAS was 32.53 and 35.15 respectively. 
 
 
 
                              Figure V. Prevalence data (70 patients) 
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Severity of OSA (Table VI) 
 
 
Of the 53 patients who were diagnosed with OSA, nearly 50% of patients had mild 
OSA. 
 
 
 
 
                                   Figure VI. Severity of OSA (53 patients) 
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OSA and Loudness of snoring (Table VII) 
 
The analysis of the AHI and ODI on the basis of the loudness of snoring did not 
reveal any association. 
 
 
OSA and Apneic Episodes (Table VIII) 
 
 
The analysis of the AHI and ODI among the 25 patients who had a history of apneic 
episodes found it to be significantly higher when compared to the AHI and ODI 
values among the 27 patients who did not have a history of apneic episodes. 
 
 
 
 
 
                 Figure VII. Severity of OSA and Apneic episodes (52 patients) 
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OSA and severity of IHD (Table IX) 
 
The mean AHI and ODI among the triple vessel disease group were higher when 
compared to the other groups. This was found to be statistically significant. 
 
 
 
 
 
 
 
 
                                 Figure VIII. OSA and severity of IHD 
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OSA and LV systolic function (Table X) 
 
Of the 53 patients with OSA, nearly 70% had normal LV systolic function. Among 
the 17 patients with LV systolic dysfunction, over 75% had moderate LV dysfunction. 
 
A comparison of the AHI and the severity of LV dysfunction showed that more 
severe OSA was present in patients with severe LV dysfunction. However, there was 
no statistically significant difference. 
The pearsons’s correlation coefficient revealed a weak negative relation between 
AHI, ODI and LVEF. 
 
 
 
                    Figure IX. OSA and LV systolic dysfunction 
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OSA and BMI (Table XI) 
 
 
 
The mean AHI and ODI were higher in the obese group as compared to the 
overweight group. 
However, the difference was not statistically significant. 
The pearsons’s correlation coefficient revealed a weak positive relation between AHI, 
ODI and BMI. 
Also, the pearsons’s correlation coefficient revealed a weak positive relation between 
AHI, ODI and weight. 
 
 
 
                                                 Figure X. OSA and BMI 
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OSA and waist circumference (Table XII) 
 
 
The data among the women revealed that the mean AHI and ODI was greater among 
those women with abdominal obesity. 
However, among the men, the AHI and ODI was less among those with abdominal 
obesity. However, there was no statistically significant difference among both groups. 
 
OSA and neck circumference (Table XIII) 
 
 
Analysis reveals that both the AHI and ODI were increased in the group with neck 
circumference more than 40 cms. 
However, there was no statistically significant difference between the groups. 
The pearsons’s correlation coefficient revealed a weak positive relation between AHI, 
ODI and neck circumference. 
 
                                  Figure XI. OSA and neck circumference 
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The significance of nocturnal desaturation in patients diagnosed with OSA  
(Table XIV) 
 
An analysis of the lowest nocturnal desaturation values among patients with LV 
systolic dysfunction did not reveal any association. 
The pearsons’s correlation coefficient revealed a weak positive relationship. 
Also, analysis of the lowest nocturnal desaturation values with severity of IHD based 
on angiography, did not reveal any association. 
 
 
 
The risk factors for OSA among IHD patients (Table XV) 
 
 
Among the various factors analysed regarding risk of OSA among IHD patients; neck 
circumference, presence of snoring and presence of apneic episodes were identified to 
be the significant risk factors. 
 
 
 
Odds ratio of  Snoring and OSA among IHD patients (Table XVI) 
 
 
Out of 70 patients, there were 53 patients diagnosed with OSA. 
Out of 70 patients, there were 54 patients who had a history of snoring. 
 
Out of the 54 patients with a history of snoring, 52 patients had OSA. 
Out of the 16 patients who did not have a history of snoring, 1 patient had OSA. 
 
In this cohort of IHD patients, the odds ratio that a person with snoring would have 
OSA was 390. 
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                                                    7. DISCUSSION 
 
 
The results indicate that sleep disordered breathing is highly prevalent among patients 
with IHD. 
 
We have used the ApneaLink device in this study. This is a portable screening device 
for OSA and has been validated previously. Its ease of use has also been 
demonstrated. 
 
The prevalence of OSA and OSAS in this cohort of patients with angiography proven 
IHD is estimated to be 75.7% and 18.6% respectively. This data is similar to previous 
studies from western populations that have estimated the prevalence of OSA among 
IHD patients to be between 50-65%.  
 
 
                           Studies showing association between OSA and IHD 
 
 
Author Name (Reference 
number in bibliography) 
 
 
              Study group characteristics 
 
 OSA prevalence 
De Olazabal (100) N= 17 male patients with IHD proven by  
angiography 
 
65% 
Andreas (101) N= 47 male patients, 3 female patients with IHD  50% 
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proven by angiography 
 
Mooe (21) N= 142 male patients with IHD proven by  
angiography 
 
61% 
Mooe (102) N= 102 female patients with IHD proven by 
angiography 
 
54% 
Present Study N= 55 male patients, 15 female patients  
with IHD proven by angiography 
 
75.7% 
 
 
 
 
However, there is a paucity of data regarding prevalence of OSAS among IHD 
patients. While more than 75% of patients in our cohort had OSA, less than 20% had 
evidence of functional impairment like morning fatigue and increased daytime 
somnolence. This suggests that in a majority of patients with OSA and IHD, snoring 
occurs without any functional impairment. Analysis of the pictorial Epworth 
sleepiness scale scores further corroborates this data.  
 
Out of the 54 patients who had a history of snoring, over 96% were diagnosed to have 
OSA. This data suggests the importance of history of snoring as a screening tool for 
OSA. While there was no association between severity of OSA and loudness of 
snoring, the severity of OSA was found to be significantly associated with presence of 
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apneic episodes with more severe OSA being present among those patients with 
history of apneic episodes. 
 
Neck circumference, presence of snoring and presence of apneic episodes were 
identified as risk factors for development of OSA among IHD patients. The Odds 
ratio that a person in this cohort who had snoring, would have OSA was 390. 
 
Among the 53 patients diagnosed with OSA, nearly 50% of patients had mild OSA. 
This is again similar to previous studies done that have estimated that more than half 
of the patients with OSA and IHD have mild OSA. 
 
Nocturnal desaturation is one of the most important consequences of OSA, especially 
in patients with IHD. Intermittent hypoxia is associated with myocardial ischemia and 
arrhythmias in patients with IHD. The mean lowest oxygen saturation among the 53 
patients with OSA in our study was 73.7 %. However, data from other studies have 
estimated the lowest saturation to be around 86%. The significance of this difference 
is yet to be confirmed. However, it was not found to be associated with either LV 
systolic function or severity of IHD. 
 
Analysis revealed that the severity of OSA was significantly associated with severity 
of IHD with patients with triple vessel disease having more severe involvement as 
compared to single and double vessel disease.. 
However, while the severity of OSA was related to severity of LV systolic 
dysfunction, BMI, waist circumference and neck circumference, it was not 
statistically significant. 
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This has to be considered in the background of the relatively small sample size. This 
could have led to a type II error that limited the power of statistical analysis. 
 
This is the first study from South Asia that attempts to study the relation between 
OSA and IHD in a cohort of patients with IHD. Also, the data regarding OSA, LV 
dysfunction, severity of IHD, patterns of sleep disordered breathing and metabolic 
parameters is novel and there have been no other previous studies regarding these 
factors from South Asia. 
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                                                    8. CONCLUSIONS 
 
 
 
1. The prevalence of OSA in the cohort of patients with angiography proven IHD 
is greatly increased as compared to the prevalence among the general 
population. 
2. This confirms the role of OSA as a significant independent modifiable risk 
factor for IHD. 
3. The severity of OSA is found to be significantly associated with the severity 
of IHD based on angiography and also, presence of apneic episodes. 
4. Neck circumference, presence of snoring and presence of apneic episodes 
were identified as risk factors for OSA in this cohort. 
5. This indicates the importance of screening for OSA among all patients with 
IHD, and especially among those with a history of snoring associated with 
apneic episodes. 
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                                                 9. LIMITATIONS 
 
 
 
We were unable to obtain a control group for the study in order to perform a case-
control analysis. This was due to the fact that we were unable to perform 
corresponding sleep studies on the required number of normal individuals. 
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                                                      11. ANNEXURE 
 
 
11.1 PATIENT INFORMATION SHEET 
 
 
Christian Medical College, Vellore 
Department of Pulmonary Medicine 
 
OBSTRUCTIVE SLEEP APNEA AND ISCHEMIC HEART DISEASE STUDY 
 
Information sheet 
 
You are being requested to participate in a study to determine the prevalence of 
obstructive sleep apnea in people with ischemic heart disease. 
If you take part what will you have to do? 
If you agree to participate in this study, your base line data will be collected including 
results of investigations like blood tests and ECG and 2D Echocardiogram. You will 
also need to undergo a physical examination conducted by the investigator. 
Subsequently, you will be instructed about the portable apnea-link device that will 
be used for over-night monitoring during the study and you will be given the 
portable device. You can use the device at your residence and there is no need for 
hospital admission. Once the study is completed, you will need to return the device 
to the investigator. 
Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are also free to decide 
to withdraw permission to participate in this study. If you do so, this will not affect 
your usual treatment at this hospital in any way.  
What will happen if you develop any study related injury? 
We do not expect any injury to happen to you because of taking part in this study. 
Will you have to pay anything extra to take part in the study?  
You will not incur any extra charges for taking part in this study.   
What happens after the study is over? 
You may or may not benefit from the study that you are a part of. However the 
conclusions drawn from this study will be useful to manage similar patients in future. 
 Will your personal details be kept confidential? 
The results of this study may be published in a medical journal but you will not be 
identified by name in any publication or presentation of results. However, your 
medical records may be reviewed by people associated with the study, should you 
decide to participate in this study.  
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11.2 PATIENT CONSENT FORM 
 
                                              Christian Medical College, Vellore 
Department of Pulmonary Medicine 
 
OBSTRUCTIVE SLEEP APNEA AND ISCHEMIC HEART DISEASE STUDY 
 
Consent Form 
 
Study Serial Number: 
Participant’s name:  
Age (in years): 
 
I_____________________________________________________________ 
son/daughter of  ___________________________________ 
 
(Please tick boxes) 
 
(i) I confirm that I have read and understood the information sheet dated for the 
above study   
and have had the opportunity to ask questions. [     ] 
(ii) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason, without my medical care or 
legal rights being affected. [     ] 
 (iii) I understand that the Investigators involved with the study, the Ethics 
Committee and the regulatory authorities will not need my permission to look at my 
health records both in respect of the current study and any further research that 
may be conducted in relation to it, even if I withdraw from the trial. I agree to this 
access. However, I understand that my identity will not be revealed in any 
information released to third parties or published. [     ] 
(iv) I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s) [     ] 
(v) I agree to take part in the above study. [     ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
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11.3 CASE PROFORMA 
 
                                             Christian Medical College, Vellore 
Department of Pulmonary Medicine 
 
OBSTRUCTIVE SLEEP APNEA AND ISCHEMIC HEART DISEASE STUDY 
 
CASE PROFORMA 
 
 
1. Date 
2. Name 
3. Age 
4. Sex 
5. Hospital number 
6. Presence of Diabetes Mellitus- Y/N 
7. Presence of Hypertension- Y/N 
8. Presence of Dyslipidemia- Y/N 
9. Presence of Thyroid Disorders- Y/N 
10. If yes, type of thyroid disorder (hyperthyroidism/ hyperthyroidism) 
11. Presence of snoring- Y/N 
12. Loudness of snoring-  
            loud as breathing/ loud as talking/ louder than talking/ very loud 
13. Frequency of snoring- 
Almost every day/ 3-4 times per week/ 1-2 times per week/ 1-2 times per 
month 
14. Does the snoring affect other people- Y/N 
15. Occurrence of breathing pauses- Y/N 
16. Frequency of breathing pauses- 
 Almost every day/ 3-4 times per week/ 1-2 times per week/ 1-2 times per 
month 
17. Presence of morning fatigue- Y/N 
18. Increased daytime somnolence- Y/N 
19. History of myocardial infarction- Y/N 
20. If yes- type: STEMI/ NSTEMI 
21. Coronary Angiogram- 
Normal/ SVD/ DVD/ TVD/ Minor artery disease 
22. Angioplasty- Y/N 
23. Stenting- Y/N 
24. CABG- Y/N 
25. Weight 
26. Height 
27. BMI 
28. Neck circumference 
29. Waist circumference 
30. Sleep study reports: AHI, ODI 
89 
 
31. 2D ECHO- Normal/ Abnormal 
32. LV ejection fraction 
33. STOPBANG score 
34. Presence of OSA- Y/N 
35. Severity of OSA 
36. Presence of Metabolic syndrome 
37. Presence of Syndrome Z 
38. Pictorial Epworth sleepiness scale score 
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11.4 MICROSOFT EXCEL DATA SHEET 
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                                                  12. LIST OF TABLES 
 
 
 
 
1. Clinical characteristics of patients- A 
 
2. Clinical characteristics of patients- B 
 
3. 2D Echocardiogram results 
 
4. Patterns of sleep disordered breathing 
 
5. Sleep study results 
 
6. Severity of OSA 
 
7. OSA and loudness of snoring 
 
8. OSA and apneic episodes 
 
9. OSA and severity of IHD 
 
10. OSA and LV systolic function 
 
11. OSA and BMI 
 
12. OSA and waist circumference 
 
13. OSA and neck circumference 
 
14. The significance of nocturnal desaturation in patients diagnosed with OSA 
 
15. The risk factors for OSA among IHD patients 
 
16. Odds ratio for snoring and OSA among IHD patients 
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4 17/01/2013 50 1 1 2 2
5 03/06/2012 53 2 1 1 2
6 11/05/2013 55 1 2 2 1
7 07/01/2013 53 1 2 2 1
8 14/09/2012 65 1 2 2 2
9 07/02/2013 62 2 1 1 1
10 04/05/2013 66 1 1 2 1
11 12/06/2013 83 1 2 2 2
12 07/05/2013 47 1 2 2 2
13 08/06/2013 74 2 1 1 1
14 10/12/2012 69 1 2 2 2
15 02/06/2013 55 1 1 2 2
16 14/01/2013 57 1 1 1 1
17 27/05/2013 58 1 1 1 2
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43 22/01/2013 65 1 2 2 2
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58 24/05/2013 55 1 2 1 2
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2 26 90 45 2 30 3
2 23 70 9 1 57
2 26.5 81 1 1 56
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1 24 82 1 1 56
2 27.3 86 0 1 58
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2 32.4 86 0 1 58
2 28.1 85 1 2 45 1
2 28 80 0 1 57
2 24.6 82 2 1 57
2 31.1 81 2 2 37 2
2 23.5 78 2 2 43 2
1 26 80 2 1 55
2 29 80 2 1 55
2 27.5 83 2 1 55
2 32 100 2 1 57
2 25.4 84 0 1 58
2 27 89 0 2 46 1
1 34 92 45 2 44 2
2 28.3 95 13 2 42 2
2 24.4 74 21 1 56
2 28.9 80 42 1 58
2 25.6 91 14 1 55
2 34 100 45 1 57
2 29.1 90 22 1 58
2 26 86 25 1 55
2 25.9 84 14 2 45 1
2 31 90 38 2 38 2
2 26.9 94 53 1 55
2 26.6 86 14 1 56
2 30.4 96 15 1 57
2 28.6 76 15 2 36 2
2 29 80 22 1 56
2 41 120 11 1 55
2 29.7 94 6 1 58
2 28.2 91 69 2 44 2
2 29 86 39 1 56
2 25 81 21 2 43 2
2 30.4 110 62 1 56
2 27.3 92 14 1 57
2 30 98 10 1 56
1 29.7 84 42 1 56
2 26 80 8 1 55
2 28.3 90 57 2 41 2
2 26.6 85 9 1 58
2 29 95 12 1 57
2 30.2 88 12 2 44 2
2 29 95 38 1 58
2 26.6 86 10 2 41 2
2 28.2 94 10 1 56
2 29 96 21 1 56
2 27.3 88 15 1 58
2 26.2 84 29 1 55
2 27.3 80 42 2 38 2
2 34 120 11 1 58
2 24.3 82 22 1 55
2 29.7 110 14 1 58
2 29.3 80 17 2 30 3
2 28.3 92 8 1 58
2 24.6 84 10 1 57
2 28.3 97 6 1 58
2 31.1 101 10 1 58
2 26.5 80 5 1 58
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28 2 9 1 2 1 1
7 2 8 1 1 2 2
16 1 12 1 2 2 2
52 2 8 1 3 2 2
39 2 6 1 2 2 2
31 1 13 1 2 1 1
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13 2 8 1 1 1 1
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9 1 12 1 1 2 2
26 2 10 1 3 1 1
48 2 9 1 3 1 1
32 2 9 1 1 1 1
9 2 8 1 1 1 1
31 2 6 1 1 1 1
48 2 9 1 2 1 1
24 2 7 1 1 1 1
11 2 5 1 1 1 1
63 1 12 1 3 1 1
39 1 12 1 3 1 1
29 2 8 1 2 1 1
62 1 12 1 3 1 1
15 2 7 1 1 1 1
14 2 10 1 1 1 1
59 2 10 1 3 2 2
15 2 6 1 1 1 1
59 2 10 1 3 1 1
10 2 10 1 1 1 1
15 2 8 1 1 1 1
15 2 8 1 1 1 1
42 2 9 1 3 1 1
15 2 8 1 1 1 1
6 2 10 1 1 1 1
28 2 6 1 2 1 1
15 2 9 1 1 1 1
24 2 9 1 2 2 2
54 2 9 1 3 1 1
29 1 13 1 1 1 1
20 2 8 1 2 1 1
8 2 10 1 1 1 1
9 1 12 1 2 2 2
9 2 6 1 1 1 1
14 2 3 1 1 1 1
11 2 3 1 1 1 1
22 2 6 1 1 1 1
11 2 6 1 1 1 1
stopbang nc wt
6 36 66
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5 36 66
6 41 70
6 40 68
4 37 63
2 39 68
3 35 58
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1 38 70
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3 35 78
3 38 72
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3 37 69
3 35 70
3 35 69
3 36 70
1 38 70
1 36 74
3 38 84
3 38 70
3 38 76
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6 40 78
7 40 74
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5 40 74
8 43 88
5 41 70
5 38 68
4 36 67
6 40 70
5 42 76
5 39 70
7 42 78
4 39 67
5 38 70
6 38 105
6 42 78
5 38 76
7 42 74
4 38 66
7 42 84
5 40 70
8 40 76
6 40 80
4 36 60
5 38 84
4 35 74
5 42 80
6 38 68
6 41 78
4 38 60
7 42 76
6 40 76
4 39 70
3 38 74
4 38 70
6 41 103
4 39 64
6 41 96
4 38 66
5 39 78
5 36 68
3 38 78
6 42 88
2 38 68
